BTIG analyst Thomas Shrader maintained a Buy rating on Bright Minds Biosciences yesterday and set a price target of $72.00. The company’s shares closed yesterday at C$80.95.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Shrader is a 3-star analyst with an average return of 1.7% and a 37.45% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Harrow Health, Denali Therapeutics, and NRX Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bright Minds Biosciences with a C$109.40 average price target, a 35.15% upside from current levels. In a report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $85.00 price target.
DRUG market cap is currently C$573.5M and has a P/E ratio of -61.22.
Read More on TSE:DRUG:
Disclaimer & DisclosureReport an Issue
- Bright Minds Biosciences’ Promising Pipeline and Strategic Expansion Justify Buy Rating
- Psychedelic: Cybin completes enrollment in CYB004 Phase 2 study
- Bright Minds initiated with a Buy at BTIG
- Bright Minds Biosciences Launches $100 Million At-The-Market Offering
- Psychedelic: Bright Minds reports preclinical BMB-201 results
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Space%20Technology%20by%20Rini_%20com%20via%20Shutterstock.jpg)